Mostrar el registro sencillo del ítem

Nanotechnology for Alzheimer disease

dc.contributor.authorLeszek J.
dc.contributor.authorAshraf G.M.
dc.contributor.authorTse W.H.
dc.contributor.authorZhang J.
dc.contributor.authorGąsiorowski K.
dc.contributor.authorÁvila-Rodriguez M.F.
dc.contributor.authorTarasov V.V.
dc.contributor.authorBarreto G.E.
dc.contributor.authorKlochkov S.G.
dc.contributor.authorBachurin S.O.
dc.contributor.authorAliev G.
dc.date.accessioned2020-09-02T22:21:45Z
dc.date.available2020-09-02T22:21:45Z
dc.date.issued2017
dc.identifier10.2174/1567205014666170203125008
dc.identifier.citation14, 11, 1182-1189
dc.identifier.issn15672050
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5082
dc.descriptionBackground: Alzheimer disease (AD) typically affects behavior, memory and thinking. The change in brain have been reported to begin approx. 10-20 years before the appearance of actual symptoms and diagnosis of AD. An early stage diagnosis and treatment of this lethal disease is the prime challenge, which is mainly halted by the lack of validated biomarkers. Method: Recent nanotechnological advancements have the potential to offer large scale effective diagnostic and therapeutic options. Targeted drug (e.g. Rivastigmine) delivery with the help of nanoparticles (NPs) in the range of 1-100 nm diameters can effectively cross the blood brain barrier with minimized side effects. Moreover, biocompatible nanomaterials with increased magnetic and optical properties can act as excellent alternative agents for an early diagnosis. With the high volume of research coming in support of the effective usage of NP based drug delivery in critical environment of CNS, it is quite likely that this approach can end up providing remarkable breakthroughs in early stage diagnosis and therapy of AD. Conclusion: In the current review, we have presented a comprehensive outlook on the current challenges in diagnosis and therapy of AD, with an emphasis on the effective options provided by biocompatible NPs as imaging contrast agents and drug carriers. © 2017 Bentham Science Publishers.
dc.language.isoen
dc.publisherBentham Science Publishers B.V.
dc.subjectAlzheimer’s disease
dc.subjectDementia
dc.subjectDrug delivery
dc.subjectNanoparticles
dc.subjectNeurofibrillary tangles
dc.subjectNeuroprotection
dc.subjectnanoparticle
dc.subjectAlzheimer disease
dc.subjectanimal
dc.subjectdrug delivery system
dc.subjecthuman
dc.subjectnanotechnology
dc.subjectAlzheimer Disease
dc.subjectAnimals
dc.subjectDrug Delivery Systems
dc.subjectHumans
dc.subjectNanoparticles
dc.subjectNanotechnology
dc.titleNanotechnology for Alzheimer disease
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85040026859.pdf
Tamaño:
2.835Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem